← Back to Search

Monoclonal Antibodies

Cohort J3 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 and day 14
Awards & highlights

Study Summary

This trial tests the safety and tolerability of a new drug in healthy Japanese people. #health #medicine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 and day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of deaths
Number of participants with AEs
Number of participants with adverse events (AEs) leading to discontinuation
+5 more
Secondary outcome measures
Area under the concentration-time curve within a dosing interval (AUC[TAU])
Maximum observed plasma concentration (Cmax)
Time of maximum observed plasma concentration (Tmax)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort J3Experimental Treatment2 Interventions
Group II: Cohort J2Experimental Treatment2 Interventions
Group III: Cohort J1Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986322
2022
Completed Phase 1
~330

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,808 Total Patients Enrolled
~9 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top